Abstract:OBJECTIVE To study the pharmacokinetics and bioequivalence of isosorbide 5-mononitrate and aspirin from compound isosorbide mononitrate sustained released tablets in healthy volunteers.METHODS Isosorbide mononitrate sustained release tablets and aspirin enteric-coated tablets were used as the reference preparations.In a randomized crossover design,single and multiple doses of test and reference preparations were given to 20 and 18 healthy male volunteers respectively. Isosorbide-5-mononitrate and salicylic acid concentrations were measured by ESI-MSD and DAD respectively. RESULTS After a single oral administration,the pharmacokinetic parameters of isosorbide 5-mononitrate test and control preparations were as following:AUC_~0→36 h (10 025.1±1 336.9) and (9 472.0±1 139.3)μg·h·L~-1 ;t_~max (4.7±1.0) and (4.5±0.8) h;c_~max (661.9±76.5) and (658.0±83.2) μg·L~-1 , respectively. For salicylic acid, the pharmacokinetic parameters were as AUC_~0→∞ (21 864±6 239) and (18 872±5 379) μg·h·L~-1 ;t_~max (0.8±0.4) and (4.7±1.0) h;c_~max (6 050±1 133) and (3 797±872)μg·L~-1 ,respectively. The relative bioavailability of isosorbide 5-mononitratte and salicylic acid were (105.9±6.4)% and (117.5±19.3)%,respectively. After multiple oral administration of test and reference preparations,the pharmacokinetic parameters were as following:AUC_~ss (10 333.5±1 519.2) and (10 410.5±1 767.5) μg·h·L~-1 ;t_~max (4.3±1.1) and (4.3±0.8) h;c_~max (724.8±95.5) and (786.7±110.0) μg·L~-1 ;c_~min (129.4±40.0) and (121.9±36.0) μg·L~-1 ;c_~av (430.6±63.3) and (433.8±73.6) μg·L~-1 ; DF (140.1±15.9)% and (155.2±20.7)%,respectively. The relative bioavailability of isosorbide 5-mononitrate was (100.5±13.0)%. CONCLUSION Compoud isosorbide mononitrate sustained release tablets showed bioequivalence for the isosorbide 5-mononitrate component with the reference preparation, and the AUC for the aspirin component was bioequivalent with that of the reference drug,but the test drug was more rapidly absorbed.

Comparative Pharmacokinetics of Isosorbide-5-Mononitrate and Isosorbide 5-Mononitrate combined with Fluctose-1,6-Diphosphate in Beagles Dogs

Improved GC for Isosorbide-5-mononitrate Determination in Dog Plasma and Its Application in Pharmacokinetics

Plasma concentration of sibutramine hydrochloride in beagle dog assayed by LC-MS and study on its pharmacokinetics

Pharmacokinetic Interaction Between Amlodipine and Irbesartan in Beagle Dogs

A comparison of the pharmacokinetics of three different preparations of total flavones of Hippophae rhamnoides in beagle dogs after oral administration

Comparison of the Pharmacokinetics Between the Two Injections of Nimodipine in Beagle

Pharmacokinetics of Domestic and Imported Isosorbide Mononitrate Sustained-Release Capsule Following a Single and Multiple Dose in Healthy Volunteers

Pharmacokinetics of piroxicam-β-cyclodextrin inclusion complexes in Beagle dogs

Comparison of Relative Bioavailability of Three Kinds of Isosorbide Mononitrate Sustained-Release Preparations

Development of Monolithic Osmotic Pump Tablet System for Isosorbide-5-Mononitrate Delivery and Evaluation of It in Vitro and in Vivo

Study on Pharmacokinetics of Melatonin Orally Disintegrating Tablets and Common Tablets in Beagle Dogs

Study on the Pharmacokinetics and Bioequivalence of Isosorbide 5-Mononitrate and Aspirin from Compound Isosorbide Mononitrate Sustained Release Tablets in Healthy Volunteers

Study on the Bioavailability and Pharmacokinetics of Guaiphenesin Sustained Release Tablets in Beagle Dogs

Pharmacokinetics of carvedilol floating tablets in Beagle dogs

Preliminary Bioequivalence of an Oral Pimobendan Solution Formulation with Reference Solution Formulation in Beagle Dogs

The stereoselective pharmacokinetics of the desmethyl‐phencynonate hydrochloride in beagle dogs

The Effect of Posaconazole and Isavuconazole on the Pharmacokinetics of Erdafitinib in Beagle Dogs by UPLC-MS/MS

Comparative single-dose pharmacokinetics of sildenafil after oral and rectal administration in healthy beagle dogs

Pharmacokinetics and bioequivalence of deferiprone extended-release tablets in Beagle dogs

Determination and Pharmacokinetics of MN9202 in Beagle Dogs

Pharmacokinetic interaction of pemetrexed disodium and oxaliplatin in Beagle dogs